Clinical trial
Phase 1 Assessment of the Biodistribution and Safety of 123-I INER in Healthy Subjects
NCT00316797 is registered in ClinicalTrials.gov with Institute for Neurodegenerative Disorders as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1 Assessment of the Biodistribution and Safety of 123-I INER in Healthy Subjects
- Lead sponsor
- Institute for Neurodegenerative Disorders
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 30, 2006
- Completion date
- January 31, 2014
- Enrollment
- 35 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.